Cite
Erbe AK, Wang W, Reville PK, et al. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017;8:675doi: 10.3389/fimmu.2017.00675.
Erbe, A. K., Wang, W., Reville, P. K., Carmichael, L., Kim, K., Mendonca, E. A., Song, Y., Hank, J. A., London, W. B., Naranjo, A., Hong, F., Hogarty, M. D., Maris, J. M., Park, J. R., Ozkaynak, M. F., Miller, J. S., Gilman, A. L., Kahl, B., Yu, A. L., & Sondel, P. M. (2017). HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in immunology, 8675. https://doi.org/10.3389/fimmu.2017.00675
Erbe, Amy K, et al. "HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy." Frontiers in immunology vol. 8 (2017): 675. doi: https://doi.org/10.3389/fimmu.2017.00675
Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017. PMID: 28659916; PMCID: PMC5466980.
Copy
Download .nbib